The Journal of Immunology · 2008 · 48 citations · 41 references
MedicineImmunologyOncologyCancer ImmunologyTumor ImmunologyTumor MicroenvironmentAntitumor T Cell ResponsesCancer ImmunoeditingCancer ImmunotherapyImmune Checkpoint RegulationTumor-infiltrating LymphocytesUveal MelanomaAntitumor Immune ActivationCancer Immunotherapy ResistanceImmune Cell ActivationImmune Checkpoint ResistanceImmune-mediated Cell LysisMelanoma ImmunotherapyMhc Class I MoleculesResistance Mechanisms To Immunotherapy
IFN-gamma, a pleiotropic immune regulator, is implicated in both tumor immune surveillance and selection of tumor variants resistant to immune control, i.e., immunoediting. In uveal melanoma patients, elevated serum levels of IFN-gamma correlate with the spread of metastasis and represent a negative prognostic marker. Treatment with IFN-gamma boosted the MHC class I presentation machinery in uveal melanoma cells but suppressed their MHC class I-restricted CTL lysis. Tumor cells exposed to IFN-gamma efficiently activated specific CTL but were less susceptible to permeabilization by perforin and exhibited a decreased capacity to bind and incorporate granzyme B. These results define a novel mechanism of resistance to granule-mediated CTL lysis in human tumors. Furthermore, the data suggest that immunoediting is not limited to genetic or epigenetic changes resulting in stable cellular phenotypes but also involves an inducible modulation of tumor cells in response to a microenvironment associated with immune activation.
41
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Vijay Shankaran, Hiroaki Ikeda, Allen T. Bruce et al. · Nature · 2001 · 2.8K citations
Life Sciences, Immunology, Oncology +12
Metalloproteinase-mediated release of human Fas ligand.
Nobuhiko Kayagaki, Tomohiko Ebata, Hiroshi Ohmoto et al. · The Journal of Experimental Medicine · 1995 · 831 citations · Full text
Life Sciences, Immunology, Pathology +15